Nanoparticle drug aims to wake up immune system against tumors
NCT ID NCT07605962
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called UI-102, which is a tiny nanoparticle designed to activate the immune system to fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments. The trial will enroll 140 participants to first find the safest dose, then see if it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
UI-102 (a nanoparticle that activates the immune system to attack tumors)
What this could lead to
If successful, this could lead to a new immunotherapy option for people with advanced solid tumors that have not responded to standard treatments.
What could go wrong
This is an early phase 1/2 trial with a small number of participants, so safety and effectiveness are not yet proven. Immune activation can also cause side effects like flu-like symptoms or inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NEXT Oncology
RECRUITINGDallas, Texas, 75039, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology
RECRUITINGHouston, Texas, 77054, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••